References
- Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
- Habermann TM, Hong F, Morrison VA, et al. Long-term results from the U.S. intergroup trial of rituximab-CHOP vs CHOP followed by maintenance vs observation in DLBCL. Ann Oncol 2008;19(Suppl.): Abstract 207.
- Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
- Marcus R, Imrie K, Solal-Céligny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
- Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607–1614.
- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456–473.
- McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma 2006;47:965–966.
- Rituximab summary of product characteristics [Internet]. 2014 January. Available from http://www.ema.europa.eu.
- Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007;109: 4171–4173.
- Aurran-Schleinitz T, Gravis G, Vittot M, et al.“One hour” rituximab infusion is safe and improves patient care and outpatient unit management.Blood 2005;106(Suppl. 1): Abstract 4759.
- Ghielmini M, Negretti L, Lerch E, et al. Infusion speed-escalation trial to give full-dose rituximab in one hour without steroids pre-medication. Blood 2005;106(Suppl. 1): Abstract 2451.
- Middleton HJ, Mollee P, Bird R, et al. Accelerated delivery of rituximab is safe on an out-patient basis. Blood 2005;106(Suppl. 1): Abstract 4777.
- Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276–3284.